Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma
Authors:
- Umberto CapitanioUCUmberto Capitanio
- Paul PerrottePPPaul Perrotte
- Claudio JeldresCJClaudio Jeldres
- Shahrokh F. ShariatSSShahrokh F. Shariat
- Philippe ArjanePAPhilippe Arjane
- Hugues WidmerHWHugues Widmer
- Francesco MontorsiFMFrancesco Montorsi
- Jean-Jacques PatardJPJean-Jacques Patard
- Pierre I. KarakiewiczPKPierre I. Karakiewicz
- 1 February 2009
- Vol. 73 (2) , 342-346
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Nephrectomy improves the survival of patients with locally advanced renal cell carcinomaBJU International, 2008
- Cytoreductive nephron‐sparing surgery does not appear to undermine disease‐specific survival in patients with metastatic renal cell carcinomaCancer, 2007
- Randomisation to protect against selection bias in healthcare trials2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Selection of Patients may Limit the Generalizability of Results from Cancer TrialsActa Oncologica, 2002
- Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell CancerNew England Journal of Medicine, 2001
- Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialThe Lancet, 2001
- A COMPARISON OF CAUSE OF DEATH DETERMINATION IN MEN PREVIOUSLY DIAGNOSED WITH PROSTATE CANCER WHO DIED IN 1985 OR 1995Journal of Urology, 2000
- Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a wholeAnnals of Oncology, 1999
- Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators.Journal of Clinical Oncology, 1994